Side-effects in women treated with adjuvant endocrine therapy for breast cancer
Many women with breast cancer prematurely discontinue adjuvant endocrine therapy, leading to increased mortality. We performed a cross-sectional survey (n = 456) within the Dutch UMBRELLA-cohort to gain insight into the prevalence of side-effects and its association with premature discontinuation. Almost all current endocrine therapy users experienced side-effects (92.7 %), most frequent were vasomotor- and musculoskeletal symptoms. The most reported reason for premature discontinuation was side-effects (88.1 %). Former treatment with chemotherapy was associated with more reported side-effects (97.2 % vs 82.5 %, ORadj 6.31), but less premature discontinuation of endocrine therapy (18.6 % vs 28.6 %, p-value 0.016).
Authors
- Marilot C. T. Batenburg (ORCID: https://orcid.org/0000-0002-5054-241X)
- Evelyn M. Monninkhof (ORCID: https://orcid.org/0000-0002-6641-7605)
- Lee Rademaker
- Rhodé M. Bijlsma (ORCID: https://orcid.org/0000-0003-0980-6652)
- Feike R. van der Leij (ORCID: https://orcid.org/0000-0001-6702-403X)
- Carmen C. van der Pol (ORCID: https://orcid.org/0000-0002-1045-2962)
- Anne M. May (ORCID: https://orcid.org/0000-0003-0643-3790)
- Helena M. Verkooijen (ORCID: https://orcid.org/0000-0001-9480-1623)
- Annemiek Doeksen
- Daniel J. Evers (ORCID: https://orcid.org/0009-0007-9973-0618)
- Rami Gal
- M.F. Ernst
Institutions
- Utrecht University (NL)
- University Medical Center Utrecht (NL)
- Alexander Monro Ziekenhuis (NL)
- Alrijne Ziekenhuis (NL)
- St. Antonius Ziekenhuis (NL)
- Ziekenhuis Groep Twente (NL)
Publication Details
- Journal
- The Breast
- Published
- 2025-02-11
- DOI
- https://doi.org/10.1016/j.breast.2025.104416
- Citations
- 8
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 14.54